Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.

Article Details

Citation

Owen RT

Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.

Drugs Today (Barc). 2016 Apr;52(4):239-48. doi: 10.1358/dot.2016.52.4.2479357.

PubMed ID
27252988 [ View in PubMed
]
Abstract

Donepezil (and other cholinesterase inhibitors [ChEIs]) and memantine are the mainstays of treatment in Alzheimer's dementia, addressing respectively, the cholinergic and glutamatergic dysregulation which underlies or results from its pathophysiology. To alleviate the pill burden and swallowing difficulties associated with the condition, a fixed drug combination of extended-release memantine and donepezil was developed. This combination was shown to be both bioequivalent to the components administered separately and could be administered sprinkled over soft food. The mode of action, pharmacokinetics, clinical efficacy and safety and tolerability of the combination are discussed together with the wider, often conflicting trial literature of combination versus monotherapy with memantine and ChEIs, their meta-analyses and treatment guidelines.

DrugBank Data that Cites this Article

Drugs